Efficacy and Safety of DNV3 (a Lymphocyte-activation Gene 3-blocking Antibody) Combined With Toripalimab and Chemotherapy in Advanced Melanoma: An Open-label, Single-arm Clinical Trial.

MedComm (2020) · 2026 · PMC12954137 · PMID 41782961

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a notable trendno p-value reported

In this advanced Chinese melanoma cohort, enriched for mucosal and acral subtypes, the combination regimen demonstrated a notable trend toward improved objective response rate relative to outcomes reported for existing immunotherapies in comparable populations.

also in 2,380 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.